Close Menu

NEW YORK (GenomeWeb) – Lucence Diagnostics said today that it has entered a partnership with genetic testing lab Bangkok Molecular Genetics to make its blood-based cancer diagnosis and screening tests available to patients in Thailand.

Under the terms of the agreement, BMG will distribute Lucence's blood tests, which involve the detection of DNA fragments shed by a tumor into the blood and target the most common cancers in Asia, such as breast, colon, lung, and nasopharyngeal cancer.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.